TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
-1.41%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.59B
AUM Growth
+$2.59B
(-7.3%)
Cap. Flow
-$80.8M
Cap. Flow
% of AUM
-3.12%
Top 10 Holdings %
Top 10 Hldgs %
43.13%
Holding
169
New
17
Increased
28
Reduced
46
Closed
8
Top Buys
| 1 |
Amgen
AMGN
|
$42.1M |
| 2 |
AbbVie
ABBV
|
$23.4M |
| 3 |
Bristol-Myers Squibb
BMY
|
$21.4M |
| 4 |
CELG
Celgene Corp
CELG
|
$13.2M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
$11.2M |
Top Sells
| 1 |
Abbott
ABT
|
$25.8M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$23.6M |
| 3 |
AGN
Allergan plc
AGN
|
$21.4M |
| 4 |
Gilead Sciences
GILD
|
$20.1M |
| 5 |
Neurocrine Biosciences
NBIX
|
$18.4M |
Sector Composition
| 1 | Healthcare | 92.75% |
| 2 | Real Estate | 2.87% |
| 3 | Financials | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$140B
| $181M | 6.96% | 2,520,281 -280,850 | -10% | -$20.1M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $158M | 6.09% | 1,513,904 +126,379 | +9% | +$13.2M |
|
|
3
Amgen
AMGN
$155B
| $150M | 5.78% | 862,174 +241,900 | +39% | +$42.1M |
|
4
Biogen
BIIB
$19.4B
| $142M | 5.48% | 445,607 -43,997 | -9% | -$14M |
|
5
Johnson & Johnson
JNJ
$427B
| $103M | 3.97% | 736,132 -62,800 | -8% | -$8.77M |
|
6
Vertex Pharmaceuticals
VRTX
$100B
| $96.5M | 3.72% | 643,762 -87,361 | -12% | -$13.1M |
|
|
ALXN
7
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $78.9M | 3.04% | 659,618 -91,287 | -12% | -$10.9M |
|
8
Merck
MRK
$210B
| $74.4M | 2.87% | 1,322,195 -151,100 | -10% | -$8.5M |
|
9
Viatris
VTRS
$12.3B
| $67.8M | 2.62% | 1,603,112 | – | – |
|
10
UnitedHealth
UNH
$281B
| $67.4M | 2.6% | 305,886 +30,060 | +11% | +$6.63M |
|
11
Incyte
INCY
$16.5B
| $65.7M | 2.53% | 693,275 | – | – |
|
12
Regeneron Pharmaceuticals
REGN
$61.5B
| $64.1M | 2.47% | 170,516 | – | – |
|
13
Illumina
ILMN
$15.8B
| $62.4M | 2.41% | 285,791 -30,900 | -10% | -$6.75M |
|
|
14
Abbott
ABT
$231B
| $45.6M | 1.76% | 798,619 -452,301 | -36% | -$25.8M |
|
15
BioMarin Pharmaceuticals
BMRN
$11.2B
| $43.7M | 1.68% | 489,745 -12,000 | -2% | -$1.07M |
|
16
Medtronic
MDT
$119B
| $40.9M | 1.58% | 506,026 -74,300 | -13% | -$6M |
|
17
Pfizer
PFE
$141B
| $35.3M | 1.36% | 975,087 +165,000 | +20% | +$5.98M |
|
18
Humana
HUM
$36.5B
| $34.4M | 1.33% | 138,556 +13,775 | +11% | +$3.42M |
|
|
AGN
19
DELISTED
Allergan plc
AGN
| $34.1M | 1.31% | 208,180 -130,799 | -39% | -$21.4M |
|
|
20
AbbVie
ABBV
$372B
| $33.5M | 1.29% | 346,313 +241,800 | +231% | +$23.4M |
|
21
Eli Lilly
LLY
$657B
| $32.4M | 1.25% | 383,099 -5,001 | -1% | -$422K |
|
22
Novartis
NVS
$245B
| $32.1M | 1.24% | 381,882 -16,780 | -4% | -$1.41M |
|
|
SHPG
23
DELISTED
Shire pic
SHPG
| $31.3M | 1.21% | 201,739 -50,374 | -20% | -$7.81M |
|
24
Teva Pharmaceuticals
TEVA
$21.1B
| $30M | 1.16% | 1,583,108 -173,450 | -10% | -$3.29M |
|
25
CVS Health
CVS
$92.8B
| $26.6M | 1.02% | 366,521 -45,370 | -11% | -$3.29M |
|